HOME ·

ABBISKO-B

ABBISKO-B (02256.HK): Lavengratinib wins EMA orphan status for ACH
Tags：
ABBISKO-B02256.HKInnovative Drugs
2026-10-21
ABBISKO-B (02256.HK): Lavengratinib shows positive interim Phase II results in achondroplasia
Tags：
ABBISKO-B02256.HKinnovative drug
2026-09-21
ABBISKO-B (02256.HK): First patient dosed in Phase I trial of pan-KRAS inhibitor ABSK211, preclinically covering multiple KRAS alterations
Tags：
ABBISKO-B02256.HKClinical Trial
2026-08-31
ABBISKO-B(02256.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 193.47 million, turned into a loss from a profit YoY
Tags：
ABBISKO-B02256.HK
2026-08-25
ABBISKO-B (02256.HK): IND application of oral pan-KRAS inhibitor ABSK211 approved by NMPA
Tags：
ABBISKO-B02256.HKClinical Trial
2026-08-19
ABBISKO-B (02256.HK): Oral Pan-KRAS Inhibitor ABSK211 Cleared by FDA for Phase I Trial in KRAS-Altered Solid Tumours
Tags：
ABBISKO-B02256.HKClinical Trial
2026-07-13
ABBISKO-B(02256.HK): Positive Preliminary Phase II Data of ABSK061 Plus ABSK043 for FGFR2-Positive Advanced Gastric Cancer Released
Tags：
ABBISKO-B02256.HKASCO 2026
2026-06-26
ABBISKO-B(02256.HK): Enters Strategic Research Collaboration and License Agreement with Eli Lilly, Total Potential Deal Value Up to USD1.9 Billion
Tags：
ABBISKO-B02256.HKstrategic cooperation
2026-06-24
ABBISKO-B (02256.HK) plans to issue in total 42.9 million shares by placement, with estimated net proceeds of HKD 517.3 million
Tags：
ABBISKO-B02256.HKNewTimeSpace
2026-04-21